Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cessation versus continuation of long-term mepolizumab in severe eosinophilic asthma
2015-002361-32Phase 3Completed
- Sponsor
- GSK
- Start
- Dec 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in eosinophilic asthma (EA) comparing Mepolizumab continuation with Placebo (mepolizumab cessation) (2 arms). Primary endpoint: Time to first clinically significant exacerbation. Started Dec 2015; status: completed.
02
Drugs
mepolizumab
03
Conditions
eosinophilic asthma (EA)
Beyond the preview
Go deeper on 2015-002361-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002361-32.